Y Intercept Hong Kong Ltd Buys Shares of 11,996 Pacira BioSciences, Inc. $PCRX

Y Intercept Hong Kong Ltd acquired a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 11,996 shares of the company’s stock, valued at approximately $287,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC acquired a new position in Pacira BioSciences during the 1st quarter worth $277,000. Gagnon Advisors LLC increased its stake in shares of Pacira BioSciences by 60.0% in the second quarter. Gagnon Advisors LLC now owns 213,402 shares of the company’s stock worth $5,100,000 after purchasing an additional 80,012 shares during the period. KLP Kapitalforvaltning AS boosted its stake in Pacira BioSciences by 48.5% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 35,200 shares of the company’s stock valued at $841,000 after purchasing an additional 11,500 shares during the period. Farther Finance Advisors LLC boosted its stake in Pacira BioSciences by 1,503.1% during the 2nd quarter. Farther Finance Advisors LLC now owns 8,160 shares of the company’s stock valued at $195,000 after purchasing an additional 7,651 shares during the period. Finally, Nuveen LLC acquired a new stake in Pacira BioSciences in the 1st quarter valued at approximately $12,884,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PCRX. Weiss Ratings reissued a “sell (d)” rating on shares of Pacira BioSciences in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Truist Financial decreased their price target on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Thursday, August 14th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $33.00.

Pacira BioSciences Trading Up 4.5%

Shares of Pacira BioSciences stock opened at $22.05 on Friday. Pacira BioSciences, Inc. has a 52-week low of $16.00 and a 52-week high of $27.64. The firm has a market capitalization of $990.77 million, a PE ratio of -7.93 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.38 and a quick ratio of 1.91. The company’s fifty day moving average price is $24.25 and its two-hundred day moving average price is $24.44.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.